Agnieszka Zajda

Ms. Agnieszka Zajda

Medical University of Lodz, Łódź, Łódzkie, Poland
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Mechanisms of Ageing and Development
Verified
Journal Article
Closed access
AZAgnieszka Zajda
Agnieszka Zajda
Kristiina HuttunenKristiina Huttunen
Kristiina Huttunen
JSJoanna Sikora
Joanna Sikora
MPMaria Podsiedlik
Maria Podsiedlik
Magdalena Markowicz-PiaseckaMagdalena Markowicz-Piasecka
Magdalena Markowicz-Piasecka

1 January 2022 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
Magdalena Markowicz-PiaseckaMagdalena Markowicz-Piasecka
Magdalena Markowicz-Piasecka
JHJohanna Huttunen
Johanna Huttunen
AZAgnieszka Zajda
Agnieszka Zajda
JSJoanna Sikora
Joanna Sikora
Kristiina HuttunenKristiina Huttunen
Kristiina Huttunen

1 January 2020 in Bioorganic Chemistry
Verified
Journal Article
Closed access
Magdalena Markowicz-PiaseckaMagdalena Markowicz-Piasecka
Magdalena Markowicz-Piasecka
JSJoanna Sikora
Joanna Sikora
AZAgnieszka Zajda
Agnieszka Zajda
Kristiina HuttunenKristiina Huttunen
Kristiina Huttunen

Verified
Journal Article
Open access
PDF file
AZAgnieszka Zajda
Agnieszka Zajda
JSJoanna Sikora
Joanna Sikora
Kristiina HuttunenKristiina Huttunen
Kristiina Huttunen
Magdalena Markowicz-PiaseckaMagdalena Markowicz-Piasecka
Magdalena Markowicz-Piasecka
Due to its high efficiency, good safety profile, and potential cardio-protective properties, metformin, a dimethyl biguanide, is the first-line medication in antihyperglycemic treatment for type 2 diabetic patients. The aim of our present study was to assess the effects of eight new sulfonamide-based derivatives of metformin on selected plasma parameters and vascular hemostasis, as well as on endothelial and smooth muscle cell function. The compounds with an alkyl chain (1–3), trifluoromethyl substituent (4), or acetyl group (5) significantly elevated glucose utilization in human umbilical endothelial cells (HUVECs), similarly to metformin. Our novel findings showed that metformin analogues 1–3 presented the most beneficial properties because of their greatest safety profile in the WST-1 cell viability assay, which was also proved in the further HUVEC integrity studies using RTCA DP. Compounds 1–3 did not affect either HUVEC or aortal smooth muscle cell (AoSMC) viability up to 3.0 mM. Importantly, these compounds beneficially affected some of the coagulation parameters, including factor X and antithrombin III activity. In contrast to the above-mentioned metformin analogues, derivatives 4 and 5 exerted more profound anticoagulation effects; however, they were also more cytotoxic towards HUVECs, as IC50 values were 1.0–1.5 mM. In conclusion, the chemical modification of a metformin scaffold into sulfonamides possessing alkyl substituents results in the formation of novel derivatives with potential bi-directional activity including anti-hyperglycemic properties and highly desirable anti-coagulant activity.

4 February 2023 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
AZAgnieszka Zajda
Agnieszka Zajda
JSJoanna Sikora
Joanna Sikora
MHMira Hynninen
Mira Hynninen
JTJanne Tampio
Janne Tampio
Kristiina HuttunenKristiina Huttunen
Kristiina Huttunen
Magdalena Markowicz-PiaseckaMagdalena Markowicz-Piasecka
Magdalena Markowicz-Piasecka